Fetal hypoxia and programming of matrix metalloproteinases.

Abstract:

:Fetal hypoxia adversely affects the brain and heart development, yet the mechanisms responsible remain elusive. Recent studies indicate an important role of the extracellular matrix in fetal development and tissue remodeling. The matrix metalloproteinases (MMPs) and their endogenous inhibitors, tissue inhibitors of metalloproteinases (TIMPs) have been implicated in a variety of physiological and pathological processes in the cardiovascular and central nervous systems. This review summarizes current knowledge of the mechanisms by which fetal hypoxia induces the imbalance of MMPs, TIMPs and collagen expression patterns, resulting in growth restriction and aberrant tissue remodeling in the developing heart and brain. Collectively, this information could lead to the development of preventive diagnoses and therapeutic strategies in the fetal programming of cardiovascular and neurological disorders.

journal_name

Drug Discov Today

journal_title

Drug discovery today

authors

Tong W,Zhang L

doi

10.1016/j.drudis.2011.09.011

subject

Has Abstract

pub_date

2012-02-01 00:00:00

pages

124-34

issue

3-4

eissn

1359-6446

issn

1878-5832

pii

S1359-6446(11)00301-1

journal_volume

17

pub_type

杂志文章,评审
  • Light-triggerable formulations for the intracellular controlled release of biomolecules.

    abstract::New therapies based on the use of biomolecules [e.g., proteins, peptides, and non-coding (nc)RNAs] have emerged during the past few years. Given their instability, adverse effects, and limited ability to cross cell membranes, delivery systems are required to fully reveal their biological potential. Sophisticated nanof...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2018.01.019

    authors: Lino MM,Ferreira L

    更新日期:2018-05-01 00:00:00

  • Stapled peptide induces cancer cell death.

    abstract::Hydrocarbon stapling could enable peptides from the key domains of natural proteins to be used therapeutically. Using the technique on a peptide involved in apoptosis, researchers have succeeded in destroying cancer cells in a mouse model of leukaemia. ...

    journal_title:Drug discovery today

    pub_type: 新闻

    doi:10.1016/S1359-6446(04)03268-4

    authors: Whelan J

    更新日期:2004-11-01 00:00:00

  • Fragment-based target screening as an empirical approach to prioritising targets: a case study on antibacterials.

    abstract::Here, we describe a novel workflow combining informatic and experimental approaches to enable evidence-based prioritising of targets from large sets in parallel. High-throughput protein production and biophysical fragment screening is used to identify those targets that are tractable and ligandable. As proof of concep...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2020.09.003

    authors: Canning P,Birchall K,Kettleborough CA,Merritt A,Coombs PJ

    更新日期:2020-09-10 00:00:00

  • Mammalian carboxylesterases: from drug targets to protein therapeutics.

    abstract::Our understanding of the detailed recognition and processing of clinically useful therapeutic agents has grown rapidly in recent years, and we are now able to begin to apply this knowledge to the rational treatment of disease. Mammalian carboxylesterases (CEs) are enzymes with broad substrate specificities that have k...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(05)03383-0

    authors: Redinbo MR,Potter PM

    更新日期:2005-03-01 00:00:00

  • Designing a bio-inspired biomimetic in vitro system for the optimization of ex vivo studies of pancreatic cancer.

    abstract::Pancreatic cancer is one of the most aggressive and lethal human malignancies. Drug therapies and radiotherapy are used for treatment as adjuvants to surgery, but outcomes remain disappointing. Advances in tissue engineering suggest that 3D cultures can reflect the in vivo tumor microenvironment and can guarantee a ph...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.01.012

    authors: Totti S,Vernardis SI,Meira L,Pérez-Mancera PA,Costello E,Greenhalf W,Palmer D,Neoptolemos J,Mantalaris A,Velliou EG

    更新日期:2017-04-01 00:00:00

  • Is the European regulatory framework sufficient to assure the safety of citizens using health products containing nanomaterials?

    abstract::The growing application of nanomaterials in healthcare products (i.e., cosmetics, medical devices, and medicinal products) has encouraged the upgrade of the regulatory framework within the European Community to better control their use and manage the risk of negative effects on human health and environment. Unfortunat...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.01.016

    authors: Musazzi UM,Marini V,Casiraghi A,Minghetti P

    更新日期:2017-06-01 00:00:00

  • Enabled clinical use of an HIV-1 attachment inhibitor through drug delivery.

    abstract::The clinical advancement of HIV-1 attachment inhibitors was hindered initially by poor bioavailability. Attempts to identify improved candidates revealed that solubility and dissolution-rate-limited absorption are barriers to achieving adequate antiviral plasma levels. This was mitigated by forming nanosized drugs or ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2014.03.025

    authors: Timmins P,Brown J,Meanwell NA,Hanna GJ,Zhu L,Kadow JF

    更新日期:2014-09-01 00:00:00

  • Computational systems biology approaches to anti-angiogenic cancer therapeutics.

    abstract::Angiogenesis is an exquisitely regulated process that is required for physiological processes and is also important in numerous diseases. Tumors utilize angiogenesis to generate the vascular network needed to supply the cancer cells with nutrients and oxygen, and many cancer drugs aim to inhibit tumor angiogenesis. An...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.09.026

    authors: Finley SD,Chu LH,Popel AS

    更新日期:2015-02-01 00:00:00

  • How do we measure pathology in PAH (lung and RV) and what does it tell us about the disease.

    abstract::The current understanding of the pathology that underlies pulmonary vascular and right ventricular remodeling in pulmonary hypertension is discussed. Although recent studies underscored the importance of intima and media remodeling and, for the first time, the relevance of perivascular inflammation, much is needed to ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2014.05.022

    authors: Tuder RM

    更新日期:2014-08-01 00:00:00

  • Filtering promiscuous compounds in early drug discovery: is it a good idea?

    abstract::The use of computational filters for excluding supposedly nonspecific and promiscuous compounds from chemical libraries is a controversial issue, because many drugs used in clinics today would never reach the market if these filters were applied. In part, this conflict could be caused by the paradigm: one-drug-one-tar...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2016.02.004

    authors: Senger MR,Fraga CA,Dantas RF,Silva FP Jr

    更新日期:2016-06-01 00:00:00

  • Systemic QSAR and phenotypic virtual screening: chasing butterflies in drug discovery.

    abstract::Current advances in systems biology suggest a new change of paradigm reinforcing the holistic nature of the drug discovery process. According to the principles of systems biology, a simple drug perturbing a network of targets can trigger complex reactions. Therefore, it is possible to connect initial events with final...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.02.004

    authors: Cruz-Monteagudo M,Schürer S,Tejera E,Pérez-Castillo Y,Medina-Franco JL,Sánchez-Rodríguez A,Borges F

    更新日期:2017-07-01 00:00:00

  • Effective pharmaceutical regulation needs alignment with doctors.

    abstract::Concerns emanating from the medical community about the safety and efficacy of biosimilars indicate an increasing distrust of the outcome of the drug regulatory process. To illustrate this, we analysed the creation of the European biosimilar regulatory framework, specifically focussing on the guidelines outlining appr...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2011.09.018

    authors: Ebbers HC,Pieters T,Leufkens HG,Schellekens H

    更新日期:2012-02-01 00:00:00

  • Miniaturized HTS technologies - uHTS.

    abstract::The transition from slow, manual, low-throughput screening to industrialized robotic ultra-high throughput screening (uHTS) in the past few years has made it possible to screen hundreds of thousands of chemical entities against a biological target in a short time-frame. The need to minimize the cost of screening has b...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(01)01807-4

    authors: Wölcke J,Ullmann D

    更新日期:2001-06-01 00:00:00

  • The development of molecular clamps as drugs.

    abstract::Some enzymes catalyze the modification of an ensemble of substrates in vivo and, as a consequence, are not ideal targets for active-site-directed drugs. One solution to inhibiting such multisubstrate enzymes would be a drug that binds tightly to only one substrate, which prevents the binding of that substrate to the e...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2006.07.011

    authors: Weiss ST,McIntyre NR,McLaughlin ML,Merkler DJ

    更新日期:2006-09-01 00:00:00

  • Stem cells and cell lines from the human auditory organ: applications, hurdles and bottlenecks in the development of regenerative therapies for deafness.

    abstract::The development of any stem-cell-based therapy (and a potential one for deafness is no exception) relies on the generation of the necessary tools: 'cell drugs' that can be safely manufactured for their clinical application. An increasing body of work has focussed on the identification, in animal models, of potential s...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2010.02.006

    authors: Rivolta MN

    更新日期:2010-04-01 00:00:00

  • Excessive intimal hyperplasia in human coronary arteries before intimal lipid depositions is the initiation of coronary atherosclerosis and constitutes a therapeutic target.

    abstract::The consensus hypothesis on coronary atherosclerosis suggests high LDL-C levels as the major cause and pursues it as the therapeutic target, explicitly assuming: (i) tunica intima of human coronaries consists of only one cell layer - endothelium, situated on a thin layer of scarcely cellular matrix; and (ii) subendoth...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.05.017

    authors: Subbotin VM

    更新日期:2016-10-01 00:00:00

  • Physicochemical properties affecting the fate of nanoparticles in pulmonary drug delivery.

    abstract::The inhaled delivery of nanomedicines has attracted much attention in the treatment of lung diseases or systemic diseases. However, there is a lack of understanding about their fate upon lung delivery. Thus, the objective of this review is to summarize physicochemical properties affecting the fate of nanoparticles aft...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2019.09.023

    authors: Liu Q,Guan J,Qin L,Zhang X,Mao S

    更新日期:2020-01-01 00:00:00

  • Mistletoe compound enters clinical trials.

    abstract::A drug has entered clinical trials that contains a recombinant version of the main extract from mistletoe, adn holds promise for cancer patients. ...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/s1359-6446(02)02571-0

    authors: Habeck M

    更新日期:2003-01-15 00:00:00

  • In vitro bioassays to evaluate beneficial and adverse health effects of botanicals: promises and pitfalls.

    abstract::This review provides an update on the promises and pitfalls when using in vitro bioassays to evaluate beneficial and adverse health effects of botanicals and botanical preparations. Important issues addressed in the paper are: (i) the type of assays and biological effects available; (ii) false-positives, false-negativ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.05.002

    authors: Prinsloo G,Papadi G,Hiben MG,de Haan L,Louisse J,Beekmann K,Vervoort J,Rietjens IMCM

    更新日期:2017-08-01 00:00:00

  • Learning from the past for TB drug discovery in the future.

    abstract::Tuberculosis drug discovery has shifted in recent years from a primarily target-based approach to one that uses phenotypic high-throughput screens. As examples of this, through our EU-funded FP7 collaborations, New Medicines for Tuberculosis was target-based and our more-recent More Medicines for Tuberculosis project ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2016.09.025

    authors: Mikušová K,Ekins S

    更新日期:2017-03-01 00:00:00

  • Graphene-based nanomaterials for drug and/or gene delivery, bioimaging, and tissue engineering.

    abstract::Here, we discuss the biomedical applications of graphene-based nanomaterials (GBNs). We examine graphene and its various derivatives, including graphene, graphene oxides (GOs), reduced graphene oxides (rGOs), graphene quantum dots (GQDs), and graphene composites, and discuss their unique properties related to their bi...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2017.04.002

    authors: Zhao H,Ding R,Zhao X,Li Y,Qu L,Pei H,Yildirimer L,Wu Z,Zhang W

    更新日期:2017-09-01 00:00:00

  • DNA-nanorobot-guided thrombin-inducing tumor infarction: raising new potential clinical concerns.

    abstract::DNA-nanorobot-guided thrombin-inducing tumor infarction (DNA NanorobotTh-ITI) is emerging as a powerful therapeutic strategy for treatment of solid cancers. The technology represents a major advance in the application of DNA nanotechnology for anticancer therapy. More importantly, the technology is being translated fr...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2020.03.005

    authors: Zheng K,Kros JM,Li J,Zheng PP

    更新日期:2020-06-01 00:00:00

  • A novel approach to identifying antiarrhythmic drug targets.

    abstract::Sudden cardiac death, secondary to ventricular fibrillation (VF), remains the leading cause of death in the USA. Recent experimental and theoretical studies suggest that VF could be caused by spiral wave re-entry. The initiation and subsequent break-up of spiral waves has been linked to electrical alternans, a phenome...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/s1359-6446(02)02567-9

    authors: Gilmour RF Jr

    更新日期:2003-02-15 00:00:00

  • Organometallic compounds in oncology: implications of novel organotins as antitumor agents.

    abstract::Since the introduction of cisplatin in cancer therapy, metal complexes and organometallic compounds have been gaining growing importance in oncology. The impressive clinical effectiveness of cisplatin is limited by significant side effects and the emergence of drug resistance. Thus, novel classic and unconventional Pt...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.02.002

    authors: Alama A,Tasso B,Novelli F,Sparatore F

    更新日期:2009-05-01 00:00:00

  • PLK1 as an oncology target: current status and future potential.

    abstract::The Polo-like kinases (PLKs) have been investigated as oncology targets for several years; however, only recently have potent inhibitors been described. Here, we report on progress in the clinical validation of the PLKs as antitumor drug targets as well as recent understanding gained regarding their synergistic roles ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2011.05.002

    authors: McInnes C,Wyatt MD

    更新日期:2011-07-01 00:00:00

  • Revival of the regulatory T cell: new targets for drug development.

    abstract::Compelling new evidence supports the idea that regulatory T cells play a major role in our immune system. Several subsets of these regulators have been identified recently. Differences in the phenotypical and functional characteristics of these subsets have immunological implications. From our growing knowledge of the...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/S1359-6446(03)03021-6

    authors: Sutmuller RP,Offringa R,Melief CJ

    更新日期:2004-04-01 00:00:00

  • Broad-scale analysis of thermodynamic signatures in medicinal chemistry: are enthalpy-favored binders the better development option?

    abstract::Thermodynamic profiles of ligand binding, particularly enthalpically favored binding signatures, have been suggested as a criterion to support the decision-making process around which compounds to select for further optimization in drug development. The concept was enthusiastically taken up, but turned out to be too s...

    journal_title:Drug discovery today

    pub_type: 杂志文章

    doi:10.1016/j.drudis.2019.01.014

    authors: Klebe G

    更新日期:2019-04-01 00:00:00

  • Histone acetyl transferases as emerging drug targets.

    abstract::Post-translational modifications, such as acetylation or phosphorylation, play a crucial role in the regulation of gene transcription in eukaryotes. Different subtypes of histone acetyl transferases (HATs) catalyze the acetylation of histones on specific lysine residues. A potential role of HATs in the pathology of ca...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.06.008

    authors: Dekker FJ,Haisma HJ

    更新日期:2009-10-01 00:00:00

  • Molecular and cellular biomarkers for angiogenesis in clinical oncology.

    abstract::Medical oncologists are increasingly using anti-angiogenic drugs, but identifying the best-suited drug and the optimal dosage and schedule for treatment of patients remain challenging issues. Circulating endothelial cells (CECs) and circulating endothelial progenitors (CEPs) are modulated in a variety of diseases incl...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2007.08.011

    authors: Bertolini F,Mancuso P,Shaked Y,Kerbel RS

    更新日期:2007-10-01 00:00:00

  • Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs.

    abstract::This review illustrates notable recent progress in the field of medicinal bioinorganic chemistry as many new approaches to the design of innovative metal-based anticancer drugs are emerging. Current research addressing the problems associated with platinum drugs has focused on other metal-based therapeutics that have ...

    journal_title:Drug discovery today

    pub_type: 杂志文章,评审

    doi:10.1016/j.drudis.2009.09.003

    authors: van Rijt SH,Sadler PJ

    更新日期:2009-12-01 00:00:00